Bertilimumab is a first-in-class human monoclonal antibody that targets and lowers eotaxin-1 levels. Eotaxin-1 is a chemokine that attracts eosiniphils to sites of inflamation - thus by blocking eotaxin-1, bertilimumab may reduce eosinophil migration or activation and thus provide a benefit to patients suffering from a variety of immunologic and inflammatory diseases. To date, bertilimumab has been well tolerated, with over 100 subjects having received bertilimumab in clinical trials, and has shown promising signs of activity in patients with moderate-to-severe bullous pemphigoid, a rare skin blistering disease. Read More 

Latest News

PRESS RELEASE May 15, 2018

Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid | Read more 



Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc. | Read more 


PRESS RELEASE April 2, 2018

Immune Pharmaceuticals Announces 2017 Financial Results | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events